Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. - Wikidata - wikimedia - TriplyDB

Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial.

Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial.

http://www.wikidata.org/entity/Q33889548

about

Vitamin D supplementation and breast cancer prevention: a systematic review and meta-analysis of randomized clinical trials Bisphosphonates and other bone agents for breast cancer Osteoporosis piece of multi-morbidity puzzle in geriatric care.Does adjuvant chemotherapy change bone mineral density and related serum biomarkers in women with breast cancer?Managing bone health in women with breast cancer under adjuvant treatment with aromatase inhibitors: pretreatment bone mineral density is important.Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.Innegligible musculoskeletal disorders caused by zoledronic acid in adjuvant breast cancer treatment: a meta-analysis.Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial Treatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumab.Osteoporosis and aromatase inhibitors: experience and future prospects The management of osteoporosis in breast cancer survivors.Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trial Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis.Osteoporosis and cancer Calcium and vitamin D supplementation and loss of bone mineral density in women undergoing breast cancer therapy.Skeletal manifestations of treatment of breast cancer.A retrospective study on screening and management of osteoporosis in breast cancer women treated with aromatase inhibitors in Libya.The efficacy of bisphosphonates in preventing aromatase inhibitor induced bone loss for postmenopausal women with early breast cancer: a systematic review and meta-analysis.Aging and osteoporosis in breast and prostate cancer.Adherence to oral endocrine treatments in women with breast cancer: can it be improved?Antiresorptive therapy in the management of cancer treatment-induced bone loss.Adjuvant Endocrine Therapy and Bone Health in Breast Cancer.Dietary Guidelines for Breast Cancer Patients: A Critical Review.Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race/ethnicity.Improvement of Bone Physiology and Life Quality Due to Association of Risedronate and Anastrozole.Managing bone mineral density with oral bisphosphonate therapy in women with breast cancer receiving adjuvant aromatase inhibition.Evaluation and management of skeletal disease in cancer care.Vitamin D threshold to prevent aromatase inhibitor-related bone loss: the B-ABLE prospective cohort study.Recommendations for antiresorptive therapy in postmenopausal patients with breast cancer: Marburg AIBL Guideline Evaluation Study (MAGES).Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper.The Relative Benefits of Tamoxifen in Older Women with T1 Early-Stage Breast Cancer Treated with Breast-Conserving Surgery and Radiation Therapy Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer

P2860

Q21089763-ED359097-1C1D-4709-9650-9BAE32BEE99C Q24203656-B956A5E8-2241-4E91-BB75-4BE9E502AE02 Q33351754-123F0BD5-2B28-4F9B-A35E-B19EC47594E5 Q33862200-E96938A2-3CD6-4A19-B400-0AC516C1BB3B Q34173455-D84E5FA9-5100-4BFB-826D-968FC8A2B056 Q35155647-14C3AA36-3FB2-4872-B2FC-73FA8B2891AC Q35173568-91333795-3F2E-4DE6-9AB9-7395F131AE8F Q35558893-EE4B8524-1BF5-4122-9C51-DEF064F8F0AC Q36162366-38B36132-5C31-47E8-9F54-8660431E76E3 Q36187103-BD5D660B-1342-4EB7-827F-89E99234ECF1 Q36333474-6BD43EED-32B4-42B2-91AD-99C96D210899 Q36405775-96C8CAC8-D661-40F4-8DB1-CC2486C824BD Q36616992-33FC1D5B-BF5E-4245-88B1-C1658FA6B5AB Q37135281-6AF2F74A-1721-4F40-848C-8C07CBB521ED Q37198504-8C3D7DD8-0762-4F76-8586-0A1DECBBC35B Q37350988-4E77E7BD-10E3-45E0-9FD1-B055A2B5E90B Q37630298-B99F1CC8-8C78-411D-A9F2-FF445581AA43 Q37653246-EE58EC95-E9AB-42D2-81D2-4C9C098C50AF Q37699857-9D58431F-5BE3-4F09-9988-9D3E7986EE78 Q37872146-039AB14B-3792-4C9A-BCA2-AE0D2F4A1E2F Q37877172-79273BD3-CDAB-4711-A842-4A10AB14FBDA Q38313112-6C697FBA-802D-4604-A8FE-0CB62447E269 Q38553766-5B387D0C-F976-45B6-8207-2AA50856C2B6 Q39436152-8D300A18-AB6C-4935-AAE5-8C25D318F8F4 Q40280431-A8790489-ED84-4E1D-B7B8-2B2CB5CF0119 Q41684442-392028D4-454B-4848-97D7-958A89499AEF Q42570772-179BC246-EACF-4EEC-A5D2-77E42BF42F22 Q50070694-FDE78AC3-B9F7-4FD2-8774-5879C6C6D932 Q50956330-B293ECC3-FB04-485D-8B9F-2330CD683E5C Q51393764-3F7A9B4C-57DD-419C-B30A-7FEFA54522D2 Q53136867-93487854-BF1D-444B-ABE4-E8B4335E4498 Q55001238-15A6C2B7-836F-4BEF-A810-9BCC5520AC60 Q57218488-DBFE37D1-412B-48A9-B005-4A4AAA402F47

P2860

Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial.

http://www.wikidata.org/entity/Q33889548

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Management of anastrozole-indu ...... BI prospective clinical trial.

@ast

Management of anastrozole-indu ...... BI prospective clinical trial.

@en

type

label

Management of anastrozole-indu ...... BI prospective clinical trial.

@ast

Management of anastrozole-indu ...... BI prospective clinical trial.

@en

prefLabel

Management of anastrozole-indu ...... BI prospective clinical trial.

@ast

Management of anastrozole-indu ...... BI prospective clinical trial.

@en

P1433

Q33889548-0F33B139-E7CA-4864-8C0C-6F860BDD274D

P1476

Q33889548-39D09D42-8C7C-4EFD-B6E6-942577A6CE82

P2093

Q33889548-0ED421DC-5431-411A-A554-6E9AF7A899E2

Q33889548-304B3414-EF23-4F3A-99BB-DCDEAEC32F73

Q33889548-32A05476-3F2B-4F3A-A185-318116B46FBE

Q33889548-37B30DBB-2257-4C6D-BE12-C4D38613D443

Q33889548-773FA162-8BC1-42CB-B816-607C0318EC35

Q33889548-9180CD5D-0146-4E76-BC09-E530DB74B89D

Q33889548-A7BE4584-1145-4419-A20D-A832CAA7D8F9

Q33889548-AFF922F2-1B0D-4CAC-B41F-734CE6327065

Q33889548-D1EF3038-4821-4610-96C0-349213CA89F3

Q33889548-DA7D5CB7-6637-4C56-B4E8-9B289F894506

P2860

Q33889548-02769EF3-2C90-4510-9C1D-62B4097C2CE8

Q33889548-02ADA8D0-E343-4961-8C9A-CD9D8406CB3A

Q33889548-0314D21A-AEC9-4D97-8268-3F81599E36D4

Q33889548-0505FF69-104D-4A10-BDF8-A6619D7B22BE

Q33889548-0FC70FEB-6E64-4F73-95CE-6007CF456D52

Q33889548-0FD4733F-8F7B-4F87-B8DC-687E91E7FB69

Q33889548-285BD983-1D0B-4BDC-BFE2-7A41BA909214

Q33889548-325AD295-41A9-44D1-8A8A-66CEAAE797F7

Q33889548-32919D5D-4055-41EB-8EC2-61E13399A235

Q33889548-34BE4D37-9C76-451F-8B08-2DCF109D47F5

P2888

Q33889548-AD525BB9-C771-4365-9C00-C40545626D9A

P304

Q33889548-8D482189-2C49-473B-80E6-FE0342AFF4F9

P31

Q33889548-6AE879B3-17B9-47F8-A9ED-C4D47BA5A197

P356

Q33889548-341FA87E-E477-42AD-892F-A81AA55D0DA8

P433

Q33889548-19BF407B-2C9B-476E-88AB-7A8512D6DF23

P478

Q33889548-425E92D1-B6C0-4C63-A584-69AB52A0D068

P50

Q33889548-088910C3-1F08-4ED0-8F8C-3E61A152C4B6

Q33889548-652B3C7E-17D2-4788-A54B-5325A8FE24B0

Q33889548-BA4800F0-24AD-414B-8E58-72E28E3F24A0

P577

Q33889548-DCD6BE8A-D796-4610-B7CF-A5B415EC6723

P5875

Q33889548-E415ED95-D935-490B-8406-9C02E98B8E6F

P6179

Q33889548-A8AA093C-DD36-4E4F-BBEC-2FAAAB80334A

P698

Q33889548-260FC460-5F91-4A89-9B3B-37500F372D8B

P932

Q33889548-D29345AE-0BD0-46A6-A9FC-DF2244853D62

P356

P1433

Breast Cancer Research

P1476

Management of anastrozole-indu ...... RBI prospective clinical trial

@en

P2093

Angeliki Sarantopoulou

http://www.w3.org/2001/XMLSchema#string

Athanassios Polychronis

http://www.w3.org/2001/XMLSchema#string

Basileios Venizelos

http://www.w3.org/2001/XMLSchema#string

Dimitrios Koukouras

http://www.w3.org/2001/XMLSchema#string

Evagelos Tzoracoleftherakis

http://www.w3.org/2001/XMLSchema#string

Grigorios Xepapadakis

http://www.w3.org/2001/XMLSchema#string

Helen Gogas

http://www.w3.org/2001/XMLSchema#string

John Misitzis

http://www.w3.org/2001/XMLSchema#string

John Papadiamantis

http://www.w3.org/2001/XMLSchema#string

Kyriakos Kalogerakos

http://www.w3.org/2001/XMLSchema#string

P2860

Epidemiology worldwide.

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

Aetiology of bone disease and the role of bisphosphonates in multiple myeloma.

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

Long-term effects of aromatase inhibitors on bone.

Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations.

Reducing the risk of bone loss associated with breast cancer treatment.

Emerging strategies in bone health management for the adjuvant patient.

P2888

P304

R24

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/BCR2565

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Christos Markopoulos

Nikolaos Siasos

P577

2010-04-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43180985

http://www.w3.org/2001/XMLSchema#string

P6179

1045867694

http://www.w3.org/2001/XMLSchema#string

P698

20398352

http://www.w3.org/2001/XMLSchema#string

P932

2879572

http://www.w3.org/2001/XMLSchema#string